Listen: A new obesity startup, an acquisition gone wrong, & the future of Teladoc

How does a startup compete with the likes of Eli Lilly and Novo Nordisk in the rapidly evolving field of weight loss drugs? And how did a major telemedicine company fall flat after its pandemic-induced rise?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound. We also dissect how Teladoc CEO Jason Gorevic parted ways with the company after spending 15 years building the telemedicine field.

For more on what we cover, here’s our article on Metsera; here’s STAT’s Obesity Drug Tracker, where you can find all of the weight loss drugs in development; and here is our analysis of what went wrong at Teledoc.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In